

Cover Story
ClinicalReal-world Evidence
By Matthew Bin Han Ong
A novel study led by Friends of Cancer Research is providing evidence that tumor response rates can be assessed across real-world data sets, bringing regulators one step closer to potentially building a framework for pre-market evaluation of cancer drugs and post-market tracking of drug performance based on real-world endpoints.
In Brief


Clinical Roundup


Drugs & Targets


NCI Trials


NCI Trials for October 2023
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- The other side of the patient portal: Reflections from a cancer center leader
- RFK Jr. floats the idea of barring government scientists from publishing in leading medical journals due to “corruption”
- Surviving cancer is often not a patient’s most challenging battle
- We catch up with Kimryn Rathmell on her first day as CEO at OSUCCC – James